

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



JACOBIO PHARMACEUTICALS GROUP CO., LTD.

加科思藥業集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1167)

SUPPLEMENTAL ANNOUNCEMENT TO THE 2021 ANNUAL REPORT AND THE 2022 INTERIM REPORT

References are made to (i) the annual report of Jacobio Pharmaceuticals Group Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) for the year ended December 31, 2021 (the “**2021 Annual Report**”); and (ii) the interim report of the Company for the six months ended June 30, 2022 (the “**2022 Interim Report**”). Unless otherwise defined, capitalized terms used herein shall have the same meanings as those set out in the 2021 Annual Report and the 2022 Interim Report.

This announcement is made to provide supplemental information to the 2021 Annual Report and the 2022 Interim Report in relation to the use of proceeds raised from the Global Offering.

Net proceeds (after deduction of underwriting commissions and related costs and expenses) from the Company’s Global Offering amounted to approximately HK\$1,421.8 million, equivalent to approximately RMB1,183.1 million including shares issued as a result of the partial exercise of the over-allotment option (the “**Net Proceeds**”). In addition to the information disclosed in the section headed “Use of Proceeds from Global Offering” in the 2021 Annual Report and the 2022 Interim Report, the Board would like to provide additional information pursuant to paragraph 11(8) of Appendix 16 to the Listing Rules in relation to the use of Net Proceeds as follows:

	Percentage of Net Proceeds	Allocation of Net Proceeds from the Global Offering in the proportion as disclosed in the Prospectus <i>RMB million</i>	Utilized Net Proceeds as at December 31, 2020 ^(Note 1) <i>RMB million</i>	Utilized Net Proceeds during the year ended December 31, 2021 ^(Note 1) <i>RMB million</i>	Unutilized Net Proceeds as at December 31, 2021 <i>RMB million</i>	Utilized Net Proceeds during the six months ended June 30, 2022 ^(Note 1) <i>RMB million</i>	Unutilized Net Proceeds as at June 30, 2022 ^(Note 2) <i>RMB million</i>
Fund registrational clinical trials and preparation for registration filings of JAB-3068 in mainland China, Hong Kong and Macau (the “Territory”)	44%	520.6	–	–	520.6	–	520.6
Fund registrational clinical trials and preparation for registration filings of JAB-3312 in the Territory	18%	213.0	–	–	213.0	–	213.0
Fund the set-up of our sales and marketing team and commercialization activities of JAB-3068 and JAB-3312 in the Territory	4%	47.3	–	–	47.3	–	47.3
Fund ongoing and planned clinical trials of JAB-8263	10%	118.3	–	31.5	86.8	6.0	80.8
Fund ongoing pre-clinical and clinical development of JAB-21822 and the preparation of its IND filing	8%	94.6	–	93.8	0.8	0.8	–
For the ongoing and planned early-stage drug discovery and development, including pre-clinical and clinical development of our other pipeline assets, discovery and development of new drug candidates	4%	47.3	–	47.3	–	–	–
Fund the planned construction of our in-house GMP-compliant manufacturing facility	8%	94.6	–	0.6	94.0	1.0	93.0
For working capital and general corporate purposes	4%	47.4	–	47.4	–	–	–
Total	100%	1,183.1	–	220.6	962.5	7.8	954.7

Note 1: Additional information provided pursuant to paragraph 11(8) of Appendix 16 to the Listing Rules in relation to the use of Net Proceeds.

Note 2: The unutilized Net Proceeds as at June 30, 2022 as disclosed in this announcement and the 2022 Interim Report were before the change in use of proceeds from the Global Offering as detailed under the section headed “Change in Use of Proceeds from the Global Offering” as set out in the 2022 Interim Report.

All unutilized Net Proceeds as at December 31, 2021 and June 30, 2022 are expected to be utilized by the end of 2025.

The Board confirmed that the supplemental information provided in this supplemental announcement does not affect any other information contained in the 2021 Annual Report and 2022 Interim Report and, save as disclosed above, the contents of the 2021 Annual Report and 2022 Interim Report remain unchanged.

On behalf of the Board
JACOBIO PHARMACEUTICALS GROUP CO., LTD.
Yinxiang WANG
Chairman

Hong Kong, October 6, 2022

As at the date of this announcement, the Board of the Company comprises Dr. Yinxiang WANG as Chairman and executive Director, Ms. Xiaojie WANG and Ms. Yunyan HU as executive Directors, Ms. Yanmin TANG, Dr. Dong LYU and Dr. Te-li CHEN as non-executive Directors, and Dr. Ruilin SONG, Dr. Ge WU and Dr. Daqing CAI as independent non-executive Directors.